Key result
Transseptal transcatheter mitral ViV resolves severe bioprosthetic degeneration in an 86-year-old with prior aortic ViV.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Transseptal transcatheter mitral valve-in-valve replacement can be successfully and safely performed in high-risk patients with degenerated surgical mitral bioprostheses and a prior transcatheter aortic valve-in-valve, provided careful multimodality imaging planning is used to avoid LVOT obstruction.
Transcatheter mitral valve-in-valve replacement has recently emerged as an increasingly common alternative for high surgical risk patients. We report a case of a successful transseptal transcatheter mitral valve-in-valve replacement for the treatment of a bioprosthetic mitral valve degeneration and severe regurgitation, in an 86-year-old patient who had undergone transcatheter aortic valve-in-valve procedure 6 years ago. This case emphasizes the crucial role of a careful preoperative assessment using multimodality imaging to plan the procedure, in a patient with higher risk of left ventricular outflow obstruction due to the previous transcatheter aortic valve-in- valve procedure.
No takes yet. Share an insight, caveat, or question.
Pereira et al. (2023) conducted a case report in Bioprosthetic mitral valve degeneration and severe regurgitation (n=1). Transseptal transcatheter mitral valve-in-valve (TMViV) replacement was evaluated on Procedural success and resolution of mitral regurgitation. Transseptal transcatheter mitral valve-in-valve replacement successfully treated severe bioprosthetic mitral valve degeneration in an 86-year-old man with a prior aortic valve-in-valve.
Synapse has enriched 10 related papers. Consider them for comparative context: